Sylvain Garciaz

10PUBLICATIONS
86CO-AUTHORS
Haematological tumoursGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)HaematologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 06, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Naval Daver, James S Blachly, Armin Ghobadi

|Jun 06, 2025
Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1.

Sylvain Garciaz, Camille Montersino, Maxence Bourgoin

|Mar 15, 2025
Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective Study.

Cassandre Petit, Jules Higue, Ziyad Acheaibi

|Jun 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

Sylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli

|May 16, 2024
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.

Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis

|Mar 28, 2024
Venetoclax Resistance in Acute Myeloid Leukemia.

Sylvain Garciaz, Marie-Anne Hospital, Yves Collette

Pageof 2

Frequent Collaborators

5 joint publications

Norbert Vey

4 joint publications

Christian Récher

3 joint publications

Sarah Bertoli

2 joint publications

Raynier Devillier